MedTrace Logo

Use of Low-dose Zolpidem in Parkinson's Disease

NCT03621046 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2020-03-27

No results posted yet for this study

Summary

This study will evaluate the motor and cognitive benefits of low-dose zolpidem in Parkinson's.

Conditions

  • Parkinson Disease

Interventions

DRUG

Zolpidem

Zolpidem is a non-benzodiazepine sedative/hypnotic agent usually prescribed for insomnia.

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • University Hospital Birmingham NHS Foundation Trust

    collaborator OTHER

  • Aston University

    lead OTHER

Principal Investigators

  • Ian M Stanford, BSc, PhD · Aston University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-20
Primary Completion
2019-12-31
Completion
2020-01-24

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03621046 on ClinicalTrials.gov